Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.66 |
| ▸ | CNR1 | P21554 | 6/20 | 0.66 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743124 | 0.88 | CNR2 (0.60) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL18039524 | 0.84 | CNR1 (0.66) | CNR2CNR1MAP2K3MAPK14HTR3E | |
| SCHEMBL2743126 | 0.83 | CNR2 (0.61) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL14143173 | 0.82 | CNR2 (0.56) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL4340056 | 0.82 | CNR2 (0.68) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL4326167 | 0.82 | CNR2 (0.68) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL4318798 | 0.81 | CNR2 (0.77) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL2743128 | 0.80 | CNR2 (0.58) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL4324493 | 0.80 | CNR2 (0.74) | CNR2CNR1METTL3 | |
| SCHEMBL4325403 | 0.80 | CNR2 (0.61) | CNR2CNR1METTL3HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2203171-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009025785-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009025785-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885MAP2K3 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.